Home › Funds › ORBIMED ADVISORS LLC › BSX

ORBIMED ADVISORS LLC position in BSX

BOSTON SCIENTIFIC CORP · Health Care

ORBIMED ADVISORS LLC reported holding 1,483,200 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$63.3M, representing 1.27% of its reported portfolio and ranking #23 among its reported holdings. ORBIMED ADVISORS LLC has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.48M sh
Reported value held$63.30M
Portfolio Weight1.27%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's BSX position evolved

ORBIMED ADVISORS LLC first disclosed a stake in BSX in Q3 2023 at 3,306,800 shares (US$174.6M). The position peaked in Q2 2025 at 2,813,200 shares, worth US$302.2M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 6 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 1,483,200 shares valued at US$63.3M — a reduction of -898,900 shares quarter over quarter.. Notable position changes include a 93% trim in Q3 2025 (shares fell 2% over the following quarter), a 1110% increase in Q4 2025 (shares fell 34% over the following quarter), a 38% trim in Q2 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.31M $174.60M New
Q4 2023 3.31M $191.17M Hold
Q1 2024 3.27M $224.17M Reduce
Q2 2024 3.27M $252.05M Hold
Q3 2024 3.27M $274.28M Hold
Q4 2024 3.16M $282.28M Reduce
Q1 2025 2.81M $283.80M Reduce
Q2 2025 2.81M $302.17M Hold
Q3 2025 200.00K $19.53M Reduce
Q4 2025 2.42M $230.68M Add
Q1 2026 2.38M $149.48M Reduce
Q2 2026 1.48M $63.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held BSX?

ORBIMED ADVISORS LLC has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in BSX?

As of Q2 2026, ORBIMED ADVISORS LLC holds 1.48M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $63.30M, representing 1.27% of its reported portfolio and ranking #23.

Has ORBIMED ADVISORS LLC been buying or selling BSX?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC reduced its position in BSX. The position peaked in Q2 2025 at 2.81M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.